Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Alliance for Wellness

Neither a doctor nor a teaching hospital

Research payments

$361,520

81 payments

Through program year 2024, Alliance for Wellness is reported as receiving $361,520 in research payments, across 81 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $283 1
2023 Research $11,755 4
2022 Research $25,515 5
2021 Research $174 1
2020 Research $53,973 15
2019 Research $269,819 55

Breakdown

Who paid Research payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $189,983 5 payments
  2. Roche TCRC, Inc. $69,456 6 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $45,085 6 payments
  4. AbbVie, Inc. $37,553 10 payments
  5. Genentech, Inc. $11,595 5 payments
  6. Supernus Pharmaceuticals, Inc. $4,226 2 payments
  7. Boehringer Ingelheim RCV GmbH & Co KG $3,622 47 payments
Studies the money was for Research payments · program years 2019–2024
  1. PoCC dose finding in Mild to Moderate AD $110,822 2 payments
  2. BI 425809 Proof of Concept in Schizophrenia $81,507 29 payments
  3. The Effect of 24Week Treatment With Basmisanil on Cognitive Impairment Associated With Schizophrenia $69,456 6 payments
  4. Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $37,270 9 payments
  5. A Long-Term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole As Maintenance Treatment in Adolescent Patients With Schizophrenia $19,340 3 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-And Active-Controlledtrial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents 13-17 Years Old With Schizophrenia $14,369 1 payment
  7. Prodromal to Mild Ad $11,595 5 payments
  8. A Phase 1, Single-Dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children 6 to 13 Years Old With Central Nervous System Disorders $9,780 1 payment
  9. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $4,226 2 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo-And Active-Controlledtrial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia $1,597 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record